ES2902951T3 - Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas - Google Patents
Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas Download PDFInfo
- Publication number
- ES2902951T3 ES2902951T3 ES14800446T ES14800446T ES2902951T3 ES 2902951 T3 ES2902951 T3 ES 2902951T3 ES 14800446 T ES14800446 T ES 14800446T ES 14800446 T ES14800446 T ES 14800446T ES 2902951 T3 ES2902951 T3 ES 2902951T3
- Authority
- ES
- Spain
- Prior art keywords
- dexamethasone
- single unit
- dosage form
- triethyl citrate
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827091P | 2013-05-24 | 2013-05-24 | |
| PCT/US2014/039319 WO2014190248A1 (en) | 2013-05-24 | 2014-05-23 | Use of sustained release dexamethasone in post-cataract surgery inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2902951T3 true ES2902951T3 (es) | 2022-03-30 |
Family
ID=51934201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14800446T Active ES2902951T3 (es) | 2013-05-24 | 2014-05-23 | Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10028965B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4082525A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6530744B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102245354B1 (cg-RX-API-DMAC10.html) |
| CN (2) | CN105407896B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2014268434B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2913336C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2902951T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014190248A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX362396B (es) | 2011-04-25 | 2019-01-15 | Icon Bioscience Inc | Guias de dosis para jeringa de inyeccion. |
| US20180177718A1 (en) | 2015-05-29 | 2018-06-28 | Envisia Therapeutics, Inc. | Implant for treatment of an ocular condition |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| CN109310680B (zh) | 2016-06-30 | 2022-11-01 | 度瑞公司 | 长效配制物 |
| JP2020059652A (ja) * | 2016-12-26 | 2020-04-16 | 参天製薬株式会社 | タフルプロストとクエン酸エステルとを含有するデポ剤 |
| EP3749386B1 (en) | 2018-02-09 | 2026-04-15 | Icon Bioscience, Inc. | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
| WO2020168106A1 (en) | 2019-02-13 | 2020-08-20 | Notable Labs, Inc. | Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer |
| IT201900003529A1 (it) * | 2019-03-11 | 2020-09-11 | Ntc S R L | Riduzione della posologia antibiotica in composizioni antibiotico/antinfiammatorio in associazione tra loro per uso oftalmico |
| US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
| US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
| US11602516B1 (en) | 2022-01-29 | 2023-03-14 | Resurge Therapeutics Inc. | Treating benign prostatic hyperplasia |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211793A (en) | 1979-03-19 | 1980-07-08 | American Cyanamid Company | Triethyl citrate solutions of PGE-type compounds |
| DE3500103C2 (de) | 1985-01-04 | 1987-01-22 | R.P. Scherer GmbH, 6930 Eberbach | Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff |
| US4889845A (en) | 1986-06-09 | 1989-12-26 | American Cyanamid Company | Vehicle for topical application of pharmaceuticals |
| ATE156703T1 (de) | 1992-11-09 | 1997-08-15 | Quest Int | Solubilisierungsmittel |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US20040024006A1 (en) | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
| US20030216303A1 (en) | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| JP2004511431A (ja) | 2000-06-28 | 2004-04-15 | アトゥル・ジェイ・シュクラ | 生物活性物質を含む生分解性ビヒクルおよび送達システム |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US6960346B2 (en) | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| ITMI20032087A1 (it) | 2003-10-27 | 2005-04-28 | Pharmafilm S R L | Film autosupportanti per uso farmaceutico ed alimentare. |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| US8541413B2 (en) | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| MX2007003968A (es) * | 2004-10-01 | 2008-03-04 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| EP2266638A3 (de) | 2009-06-25 | 2014-08-13 | Biotronik VI Patent AG | Biokorrodierbares Implantat mit einer aktiven Beschichtung |
| WO2011081712A1 (en) | 2009-12-31 | 2011-07-07 | Boston Scientific Scimed, Inc. | Cryo activated drug delivery and cutting balloons |
| MX362396B (es) * | 2011-04-25 | 2019-01-15 | Icon Bioscience Inc | Guias de dosis para jeringa de inyeccion. |
| WO2013058838A2 (en) * | 2011-06-10 | 2013-04-25 | Wong Vernon G | Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer |
| LT2717914T (lt) * | 2011-06-10 | 2020-03-25 | Ramscor, Inc. | Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai |
| DK3003285T3 (en) | 2013-06-03 | 2022-04-04 | Mcneil Ab | Fast farmaceutisk dosisform til frigivelse af mindst to aktive farmaceutiske ingredienser i mundhulen |
-
2014
- 2014-05-23 CA CA2913336A patent/CA2913336C/en active Active
- 2014-05-23 EP EP21215082.5A patent/EP4082525A1/en not_active Withdrawn
- 2014-05-23 ES ES14800446T patent/ES2902951T3/es active Active
- 2014-05-23 WO PCT/US2014/039319 patent/WO2014190248A1/en not_active Ceased
- 2014-05-23 CN CN201480041856.1A patent/CN105407896B/zh active Active
- 2014-05-23 EP EP14800446.8A patent/EP3003318B1/en active Active
- 2014-05-23 CN CN201910639315.3A patent/CN110339153A/zh active Pending
- 2014-05-23 KR KR1020157036698A patent/KR102245354B1/ko active Active
- 2014-05-23 JP JP2016515111A patent/JP6530744B2/ja active Active
- 2014-05-23 US US14/893,381 patent/US10028965B2/en active Active
- 2014-05-23 AU AU2014268434A patent/AU2014268434B2/en active Active
-
2018
- 2018-06-26 US US16/018,931 patent/US10159683B2/en active Active
- 2018-12-10 US US16/215,579 patent/US20190105330A1/en not_active Abandoned
-
2022
- 2022-09-20 US US17/948,842 patent/US20230078906A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160040471A (ko) | 2016-04-14 |
| CN110339153A (zh) | 2019-10-18 |
| EP4082525A1 (en) | 2022-11-02 |
| WO2014190248A1 (en) | 2014-11-27 |
| CA2913336A1 (en) | 2014-11-27 |
| US20230078906A1 (en) | 2023-03-16 |
| CN105407896B (zh) | 2019-08-27 |
| CN105407896A (zh) | 2016-03-16 |
| US10028965B2 (en) | 2018-07-24 |
| CA2913336C (en) | 2020-12-15 |
| EP3003318A1 (en) | 2016-04-13 |
| AU2014268434B2 (en) | 2018-11-22 |
| US20190105330A1 (en) | 2019-04-11 |
| US20180303851A1 (en) | 2018-10-25 |
| JP6530744B2 (ja) | 2019-06-12 |
| US10159683B2 (en) | 2018-12-25 |
| EP3003318B1 (en) | 2021-12-22 |
| KR102245354B1 (ko) | 2021-04-30 |
| EP3003318A4 (en) | 2017-01-04 |
| US20160120879A1 (en) | 2016-05-05 |
| AU2014268434A1 (en) | 2015-12-10 |
| JP2016526039A (ja) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230078906A1 (en) | Sustained release dexamethasone formulation | |
| US11439590B2 (en) | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| JP2020063236A (ja) | 後眼部障害を処置するための方法およびデバイス | |
| US11510916B2 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| JP2019501200A (ja) | 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス | |
| KR20200000487A (ko) | 주사용의 안정한 보존제-비함유 산동 및 항-염증 용액 | |
| AU2003279055A1 (en) | Methods for treatment and/or prevention of retinal disease | |
| JP2021121608A (ja) | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 | |
| TW202400215A (zh) | 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案 | |
| US20160175323A1 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| US20160243031A1 (en) | Pharmaceutical ophthalmic compositions and methods for fabricating thereof | |
| KR20180126087A (ko) | 약학적 안과용 조성물 및 그의 제조 방법 | |
| JP2016526039A5 (cg-RX-API-DMAC10.html) | ||
| US20190105320A1 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| US20190111045A1 (en) | Pharmaceutical ophthalmic compositions and methods for fabricating thereof | |
| JP2023179508A (ja) | 眼感染症を予防するための抗生物質溶液および注射方法 | |
| HK40008204A (en) | Dexamethasone unit dosage form, kit and use for post-cataract surgery inflammation | |
| US9814673B2 (en) | Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof |